Special Issue "Antibody Engineering for Cancer Immunotherapy".
Silvia CrescioliAnn L WhiteSophia N KaragiannisPublished in: Antibodies (Basel, Switzerland) (2022)
Since the approval of Rituximab in the late 1990s, the first chimeric monoclonal antibody for the treatment of non-Hodgkin lymphoma, antibody engineering for cancer immunotherapy has become a rapidly growing field, with almost 50 antibody therapeutics approved in the USA and EU and hundreds undergoing testing in clinical trials [...].